Financial health
- Operating income covered interest expense -69.9× in the latest year.
CBIO Financials CRESCENT BIOPHARMA, INC.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $11M | $153942 | 0.0% | -1407.5% | 0.1% | 0.1% | -$72M | — | $213M |
| 2024 | — | $37879 | — | — | -0.2% | 0.1% | -$31M | — | $35M |
| 2023 | — | $36899 | — | — | 0.1% | 0.1% | -$35M | — | $42M |
| 2022 | — | -$47M | — | — | -108.8% | -90.1% | -$47M | — | $48M |
| 2021 | — | -$63M | — | — | -77.7% | -67.2% | -$58M | — | $90M |
| 2020 | — | -$51M | — | — | -39.8% | -35.7% | -$39M | — | $137M |
| 2019 | — | -$58M | — | — | -37.5% | -34.5% | -$52M | — | $158M |
| 2018 | — | -$48M | — | — | -23.5% | -22.5% | -$43M | — | $210M |
| 2017 | — | -$33M | — | — | -27.8% | -25.9% | -$30M | — | $124M |
| 2016 | — | -$32M | — | — | -90.1% | -75.0% | -$30M | — | $40M |
| 2015 | — | -$13M | — | — | -31.6% | -26.3% | -$9M | — | $47M |
| 2014 | — | -$11M | — | — | -21.9% | -19.4% | — | — | $55M |
| 2014 | — | -$68M | — | — | -123.5% | -117.8% | -$63M | — | $57M |
| 2013 | — | -$11M | — | — | -364.8% | -200.7% | — | — | $2M |
| 2012 | — | $4M | — | — | 29.2% | — | — | — | $17M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$25M | — | — | -15.2% | -13.6% | -$19M | — | $172M |
| Mar '26 | $1M | -$23M | 0.0% | -2380.1% | -12.7% | -11.7% | -$9M | — | $189M |
| Dec '25 | — | -$23M | — | — | -11.5% | -9.7% | -$27M | — | $213M |
| Sep '25 | — | -$25M | — | — | -21.1% | -17.8% | -$18M | — | $133M |
| Jun '25 | $0 | -$22M | — | — | -15.6% | -13.8% | -$17M | — | $153M |
| Mar '25 | $0 | -$15M | — | — | 50.2% | -252.8% | -$11M | — | $22M |
| Dec '24 | $0 | -$18M | — | — | 115.4% | -50.2% | -$6M | — | $35M |
| Sep '24 | — | -$10M | — | — | 754.6% | -62.6% | -$8M | — | $14M |
| Jun '24 | — | -$10M | — | — | -50.3% | -41.3% | -$9M | — | $22M |
| Mar '24 | — | -$11M | — | — | -37.1% | -31.4% | -$11M | — | $31M |
| Sep '23 | — | -$9M | — | — | -19.8% | -17.3% | -$9M | — | $49M |
| Jun '23 | — | -$8M | — | — | -15.1% | -13.4% | -$7M | — | $58M |
| Mar '23 | — | -$10M | — | — | -16.7% | -15.0% | -$12M | — | $65M |
| Sep '22 | — | -$9M | — | — | -17.7% | -15.2% | -$9M | — | $52M |
| Jun '22 | — | -$13M | — | — | -23.8% | -20.4% | -$16M | — | $60M |
| Mar '22 | — | -$15M | — | — | -21.5% | -18.0% | -$14M | — | $77M |
| Sep '21 | — | -$17M | — | — | -17.9% | -16.1% | -$17M | — | $102M |
| Jun '21 | — | -$14M | — | — | -12.8% | -11.6% | -$14M | — | $119M |
| Mar '21 | — | -$14M | — | — | -11.4% | -10.3% | -$14M | — | $132M |
| Dec '20 | — | -$16M | — | — | -12.1% | -10.9% | -$10M | — | $137M |
Valuation over time
How the market has priced CBIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 15787.6× (Jun '25) to 4924.6× (Sep '26).
- The price-to-sales ratio has risen from 40.4× (Dec '25) to 69.9× (Sep '26).
P/E
P/S
Frequently asked questions
Is CBIO growing its revenue and profit?
See the revenue and net-income charts above for CRESCENT BIOPHARMA, INC.'s multi-year trend.
How much debt does CBIO have?
As of FY2025, CRESCENT BIOPHARMA, INC. reported — of total debt against $213M of cash; operating income covered interest expense -69.9×.
What is CBIO's profit margin?
In FY2025, gross margin was —, operating margin -1407.5%, and net margin 1.4%.
What is CBIO's P/E ratio?
As of Sep '26, CRESCENT BIOPHARMA, INC. traded at a price-to-earnings ratio of about 4924.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.